MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, J.-M.
Right arrow Articles by Hait, W. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, J.-M.
Right arrow Articles by Hait, W. N.

Vol. 60, Issue 4, 674-680, October 2001

Activation of Phospholipase C Induces the Expression of the Multidrug Resistance (MDR1) Gene through the Raf-MAPK Pathway

Jin-Ming Yang, Andrew D. Vassil, and William N. Hait

The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, Departments of Medicine and Pharmacology, New Brunswick, New Jersey

Resistance to multiple, unrelated cancer chemotherapeutic drugs can be mediated by P-glycoprotein, the MDR1 gene product. Numerous substances, including chemotherapeutic drugs, heavy metals, growth factors, activated oncogenes, or changes in temperature increase MDR1 gene expression. Because several of these factors regulate cellular function through the activation of phospholipase C (PLC), we postulated that PLC-mediated signaling could be central to regulating the expression of MDR1. Transfection of NIH 3T3 cells with a pMJ30-PLC-gamma 1 expression vector increased the activity of the MDR1 promoter by 2- to 10-fold. PLC-mediated activation required a region between -106 and -99 of the MDR1 promoter. Treatment of cotransfected cells with platelet-derived growth factor further enhanced the activity of the MDR1 promoter. The stimulatory effect of PLC on the MDR1 promoter was increased by cotransfection with constitutively active v-raf and was blocked by the dominant-negative mutant, c-Raf-C4. The activity of mitogen-activated protein kinase (MAPK) was also increased in PLC-gamma 1-transfected cells. Furthermore, PD-98059 and U0126, two MAPK inhibitors, blocked PLC-gamma 1-induced expression of MDR1. The results of Northern blot analysis showed that activation of PLC by heat shock and growth factors increased expression of endogenous MDR1 mRNA in human renal carcinoma cells. These effects were blocked by inhibitors of the PLC-MAPK pathway. In summary, our results indicate for the first time that activation of PLC by a variety of cellular stimuli can regulate the expression of MDR1 and that the transcriptional modulation of MDR1 expression by PLC is mediated by the Raf-MAPK pathway.


Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J Clin PharmacolHome page
R. Callaghan, E. Crowley, S. Potter, and I. D. Kerr
P-glycoprotein: So Many Ways to Turn It On
J. Clin. Pharmacol., March 1, 2008; 48(3): 365 - 378.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. T. Buckley, F. Sekiya, Y. J. Kim, S. G. Rhee, and K. K. Caldwell
Identification of Phospholipase C-{gamma}1 as a Mitogen-activated Protein Kinase Substrate
J. Biol. Chem., October 1, 2004; 279(40): 41807 - 41814.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Mahadevan and A. F. List
Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies
Blood, October 1, 2004; 104(7): 1940 - 1951.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Z. Zhang, J.-Y. Wu, W. N. Hait, and J.-M. Yang
Regulation of the Stability of P-Glycoprotein by Ubiquitination
Mol. Pharmacol., September 1, 2004; 66(3): 395 - 403.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Wu, W. N. Hait, and J.-M. Yang
Small Interfering RNA-induced Suppression of MDR1 (P-Glycoprotein) Restores Sensitivity to Multidrug-resistant Cancer Cells
Cancer Res., April 1, 2003; 63(7): 1515 - 1519.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
J.-M. Yang, Z. Xu, H. Wu, H. Zhu, X. Wu, and W. N. Hait
Overexpression of Extracellular Matrix Metalloproteinase Inducer in Multidrug Resistant Cancer Cells
Mol. Cancer Res., April 1, 2003; 1(6): 420 - 427.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics